Annexon’s (ANNX) Overweight Rating Reiterated at Cantor Fitzgerald

Annexon (NASDAQ:ANNX)‘s stock had its “overweight” rating reissued by equities research analysts at Cantor Fitzgerald in a report released on Friday,Benzinga reports.

Several other equities research analysts also recently issued reports on ANNX. HC Wainwright reiterated a “buy” rating and issued a $30.00 target price on shares of Annexon in a research note on Friday. Needham & Company LLC reaffirmed a “buy” rating and issued a $16.00 price objective on shares of Annexon in a research report on Friday. Six investment analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has an average rating of “Buy” and an average target price of $15.80.

Annexon Stock Down 1.9 %

Shares of NASDAQ:ANNX traded down $0.12 during midday trading on Friday, hitting $6.21. The stock had a trading volume of 78,210 shares, compared to its average volume of 1,810,987. The company has a market cap of $656.09 million, a P/E ratio of -5.05 and a beta of 1.23. Annexon has a 12 month low of $2.27 and a 12 month high of $8.40. The business’s 50-day simple moving average is $6.89 and its 200-day simple moving average is $5.90.

Annexon (NASDAQ:ANNX) last announced its quarterly earnings data on Monday, August 12th. The company reported ($0.23) EPS for the quarter, meeting analysts’ consensus estimates of ($0.23). As a group, equities analysts predict that Annexon will post -0.97 earnings per share for the current year.

Insider Transactions at Annexon

In related news, EVP Ted Yednock sold 5,500 shares of the firm’s stock in a transaction dated Thursday, September 5th. The shares were sold at an average price of $5.64, for a total transaction of $31,020.00. Following the transaction, the executive vice president now directly owns 10,000 shares of the company’s stock, valued at approximately $56,400. This trade represents a 35.48 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Over the last quarter, insiders have sold 20,908 shares of company stock worth $135,768. Company insiders own 12.67% of the company’s stock.

Institutional Trading of Annexon

A number of institutional investors have recently bought and sold shares of the business. Ameritas Investment Partners Inc. boosted its stake in shares of Annexon by 78.2% in the first quarter. Ameritas Investment Partners Inc. now owns 6,718 shares of the company’s stock valued at $48,000 after buying an additional 2,949 shares during the period. Sandia Investment Management LP bought a new stake in shares of Annexon during the 2nd quarter valued at $49,000. Victory Capital Management Inc. acquired a new stake in shares of Annexon during the 2nd quarter worth $51,000. Principal Financial Group Inc. bought a new position in shares of Annexon in the second quarter worth $56,000. Finally, Comerica Bank acquired a new position in Annexon in the first quarter valued at about $72,000.

About Annexon

Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.